hydroxychloroquine - for COVID-19 mild to moderate method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical improvement 3.43 [1.10, 10.70]> 10%1 study (1 / -)98.3 %highnot evaluable lowcrucial-
clinical worsening 0.58 [0.07, 5.05]< 158%2 studies (2 / -)68.6 %highnot evaluable lowcrucial-
deaths 1.20 [0.40, 3.64]< 10%1 study (1 / -)37.1 %some concernnot evaluable moderatecrucial-
PCR-negative conversion 0.46 [0.04, 5.75]> 10%1 study (1 / -)27.7 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 0.46 [0.04, 5.75]> 10%1 study (1 / -)27.7 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 3.43 [1.10, 10.70]> 10%1 study (1 / -)98.3 %highnot evaluable lowimportant-
radiologic progression 0.57 [0.13, 2.50]< 10%1 study (1 / -)77.1 %some concernnot evaluable moderateimportant-

OLD safety endpoints 00

diarrhea and abnormal liver function 1.45 [0.26, 8.01]< 10%1 study (1 / -)33.4 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 90 90